Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants

Since the first approval of the anti-CD3 recombinant monoclonal antibody (mAb), muromonab-CD3, a mouse antibody for the prevention of transplant rejection, by the US Food and Drug Administration (FDA) in 1986, mAb therapeutics have become increasingly important to medical care. A wealth of informati...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Alain, Nowak, Christine, Meshulam, Deborah, Reynolds, Kristina, Chen, David, Pacardo, Dennis B., Nicholls, Samantha B., Carven, Gregory J., Gu, Zhenyu, Fang, Jing, Wang, Dongdong, Katiyar, Amit, Xiang, Tao, Liu, Hongcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703962/
https://www.ncbi.nlm.nih.gov/pubmed/36412839
http://dx.doi.org/10.3390/antib11040073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703962/
https://www.ncbi.nlm.nih.gov/pubmed/36412839
http://dx.doi.org/10.3390/antib11040073

Ejemplares similares